AlphAIalphai — Financial news for AI agents
financialcontent.comAUG 66 min read$ASTH

Astrana Health (NASDAQ:ASTH) Beats Q2 CY2026 Non

Astrana Health (NASDAQ:ASTH) reported Q2 CY2026 revenue of $972.5 million, up 48.5% year on year but below market expectations. Next-quarter revenue guidance was $1.02 billion, about 1.1% under analysts’ estimates. Non-GAAP EPS was $0.80, up 9.6% versus consensus. Shares rose 5.1% to $35.89 after results.

Original reporting
financialcontent.com
Published Aug 6, 2026, 9:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 9:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Astrana Health (NASDAQ:ASTH) Beats Q2 CY2026 Non — source image
Source · financialcontent.com
Decision brief

The 30-second read

$ASTHNeutralMed
01

Why it matters

Q2 shows strong YoY revenue growth but a revenue miss and slightly underwhelming next-quarter revenue guidance, while non-GAAP EPS beat and adjusted operating margin was relatively stable sequentially.

02

Market read

Traders can reassess near-term revenue expectations using the $1.02B next-quarter guidance and weigh it against the $0.80 non-GAAP EPS beat and stable adjusted operating margin.

03

What to watch

The article highlights adjusted operating margin deterioration over longer horizons; traders may focus on whether cost discipline can reverse that trend, not just the single-quarter print.

Relevance 7/10Novelty 7/10Timing: after-hours/next-session reaction to Q2 results and next-quarter revenue guidance

Background

Astrana Health (formerly Apollo Medical Holdings) runs a technology-powered healthcare platform focused on physician-centric, value-based care.

Company-level read

Ticker impact

$ASTHNeutralMedium confidence
Context

Astrana Health reported Q2 CY2026 revenue of $972.5M (48.5% YoY) but guided next-quarter revenue to $1.02B, 1.1% below estimates.

Expected impact

Likely choppy trading, with upside support from the EPS beat and downside risk from the revenue guidance miss.

Evidence & confidence

The article provides concrete Q2 results (revenue miss, EPS beat) and a specific next-quarter revenue guidance shortfall versus analysts, plus notes the stock rose 5.1% immediately after results.

Market effects

Sector

Signals continued demand strength in physician-centric, value-based healthcare services, but margin pressure remains a watch item.

Regional

No specific regional spillover described beyond US healthcare services sentiment.

Global

Limited global relevance; story is company-specific within US healthcare services.

Counterpoint

What could challenge this read

The revenue guidance miss is small (1.1% below estimates) and EPS beat plus stable adjusted operating margin could outweigh the top-line concern.

Key entities

  • company
    Astrana Health

    NASDAQ-listed healthcare services company reporting Q2 CY2026 results and next-quarter revenue guidance.

  • executive
    Brandon Sim

    CEO who commented on Q2 results reflecting the company’s physician-centric, AI-native operating system.

Read at source← All news

Related articles

AUG 13
$ASTHMedAI 8/10

Astrana Health (ASTH) Q2 2026 Earnings Call Transcript

Astrana Health (ASTH) reported Q2 2026 revenue of $972.5M, up 49% YoY, and adjusted EBITDA of $68.9M, up 43%. Adjusted EPS was $0.80. Six-month free cash flow was $92.9M. The company reaffirmed full-year revenue guidance of $3.8B to $4.1B and raised adjusted EBITDA guidance to $255M to $280M. Net leverage was 2.26.

fool.com7 min
AUG 7
$ASTHMedAI 8/10

Astrana Health Inc (ASTH) (Q2 2026) Earnings Call Highlights: Record EPS and Raised

Astrana Health Inc (ASTH) reported Q2 2026 results with record EPS and raised guidance, according to management on its earnings call. The company cited a one-time $15 million Q2 revenue reduction tied to CMS adjustments for ACO REACH 2025 billing, with immaterial net EBITDA impact. It also discussed Medicaid membership attrition, commercial cost trends, and wide Q4 2026 EBITDA guidance of $47-$67 million.

yahoo.com4 min
AUG 6
$ASTHHigh

Astrana Health, Inc. (ASTH): Results of Operations and Financial Condition

Astrana Health, Inc. (ASTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622348d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Astrana Health, Inc. Reports Second Quarter 2026 Results Company to Host Conference Call on Thursday, August 6, 2026, at 2:30 p.m. PT/5:30 p.m. ET · Reports revenue of $972.5 million, up 49% year-over-year, net income of

SEC EDGAR 8-K6 min
AUG 23
$TLRYMed

Tilray Posted Record Fiscal 2026 Revenue -- Why Isn't the Stock Rallying?

Tilray Brands reported record fiscal 2026 revenue of $915 million, up 11%, and adjusted EBITDA of $61.1 million, also up 11%. Adjusted net income nearly doubled to $12.2 million, but missed analyst estimates. GAAP net loss was $49.6 million. Management expects fiscal 2027 adjusted EBITDA of $68M-$75M. Cannabis sales represent 29% of total revenue.

yahoo.com3 min
AUG 23
$MDTMedAI 8/10

Medtronic vs. Tenet Healthcare: Which Healthcare Stock Offers Better Long-Term Growth?

Medtronic (MDT) and Tenet Healthcare (THC) present distinct growth prospects. MDT reported its highest annual revenue growth in a decade, driven by cardiac ablation solutions and investments in innovation. THC saw a 52.2% increase in adjusted EPS and 6.8% revenue growth, with margin expansion in hospitals. Investors must choose between MDT's innovation-led recovery and THC's operational improvements.

yahoo.com3 min